Sars-cov-2 vaccines
US-2024408193-A1 · Dec 12, 2024 · US
Compositions and methods for treating merkel cell carcinoma (mcc) using hla class i specific epitopes
US2023248814A1 · US · A1
| Field | Value |
|---|---|
| Publication number | US-2023248814-A1 |
| Application number | US-202117928649-A |
| Country | US |
| Kind code | A1 |
| Filing date | Jun 1, 2021 |
| Priority date | Jun 1, 2020 |
| Publication date | Aug 10, 2023 |
| Grant date | — |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The subject matter disclosed herein is generally directed to epitopes that specifically bind to subject specific HLA class I molecules in MCC. The epitope identified is specific for MCC and is encoded for in the Merkel Cell Polyomavirus (MCPyV) large T antigen (MCPyV LT).
First claim
Opening claim text (preview).
What is claimed is: 1 . An immunogenic composition for the treatment of Merkel Cell Carcinoma (MCC) comprising a peptide or polynucleotide encoding for the peptide derived from the OBD polypeptide of Merkel Cell Polyomavirus (MCPyV) large T antigen (MCPyV LT). 2 . The immunogenic composition of claim 1 , wherein the peptide corresponds to amino acids 341-349 of MCPyV LT. 3 . The immunogenic composition of claim 1 , wherein the peptide comprises TSDKAIELY (SEQ ID NO:1). 4 . The immunogenic composition of any of claims 1 to 3 , wherein the peptide is an HLA*A01:01-restricted class I epitope. 5 . The immunogenic composition of any of claims 1 to 4 , wherein the peptide is presented on an antigen presenting cell. 6 . The immunogenic composition of claim 5 , wherein the antigen presenting cell is a dendritic cell. 7 . The immunogenic composition of any of claims 1 to 4 , wherein the peptide is presented by an HLA tetramer. 8 . An ex-vivo immune cell for the treatment of Merkel Cell Carcinoma (MCC) comprising a chimeric antigen receptor (CAR), endogenous T cell receptor (TCR) or exogenous T cell receptor (TCR) specific for a peptide derived from the OBD polypeptide of Merkel Cell Polyomavirus (MCPyV) large T antigen (MCPyV LT). 9 . The immune cell of claim 8 , wherein the peptide corresponds to amino acids 341-349 of MCPyV LT. 10 . The immune cell of claim 8 , wherein the peptide comprises TSDKAIELY (SEQ ID NO: 1). 11 . The immune cell of any of claims 8 to 10 , wherein the peptide is an HLA*A01:01-restricted class I epitope. 12 . The immune cell of any of claims 8 to 11 , wherein the immune cell is a T cell or NK cell. 13 . The immune cell of any of claims 8 to 12 , wherein the immune cell is an autologous T cell. 14 . An antibody for the treatment of Merkel Cell Carcinoma (MCC) specific for a peptide derived from the OBD polypeptide of Merkel Cell Polyomavirus (MCPyV) large T antigen (MCPyV LT). 15 . The antibody of claim 14 , wherein the peptide corresponds to amino acids 341-349 of MCPyV LT. 16 . The antibody of claim 14 , wherein the peptide comprises TSDKAIELY (SEQ ID NO:1). 17 . The antibody of any of claims 14 to 16 , wherein the peptide is an HLA*A01:01-restricted class I epitope. 18 . The antibody of any of claims 14 to 17 , wherein the antibody is a bispecific antibody or antibody drug conjugate. 19 . The antibody of claim 18 , wherein the bi-specific antibody is a bi-specific T-cell engager (BiTE). 20 . A method of treatment comprising administering the immunogenic composition, immune cell or antibody of any of claims 1 to 19 to a subject in need thereof. 21 . The method of claim 20 , further comprising administering a treatment that increases HLA class I expression prior or concurrently, wherein the treatment is selected from the group consisting of an interferon gamma therapy and a USP7 inhibitor.
Assignees
Inventors
Classifications
- A61K39/12Primary
Viral antigens · CPC title
T-cell receptor (TcR)-CD3 complex · CPC title
Papillomaviridae (F); Polyomaviridae (F), e.g. SV40, BK virus or JC virus · CPC title
Antigen presenting cells [APCs], e.g. dendritic cells or macrophages · CPC title
Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US2023248814A1 cover?
- The subject matter disclosed herein is generally directed to epitopes that specifically bind to subject specific HLA class I molecules in MCC. The epitope identified is specific for MCC and is encoded for in the Merkel Cell Polyomavirus (MCPyV) large T antigen (MCPyV LT).
- Who is the assignee on this patent?
- Broad Inst Inc, Dana Farber Cancer Inst Inc
- What technology area does this patent fall under?
- Primary CPC classification A61K39/12. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Thu Aug 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).